Skip to main content
Image
Photo of Committee panel

Hearing on "Lives Worth Living: Addressing the Fentanyl Crisis, Protecting Critical Lifelines, and Combatting Discrimination Against Those with Disabilities"

Date:
Location:
John D. Dingell Hearing Room 2123 Rayburn House Office Building

The Subcommittee on Health of the Committee on Energy and Commerce held a hearing on Wednesday, February 1, 2023 at 10 a.m. in the John D. Dingell Hearing Room, 2123 Rayburn House Office Building. The hearing is entitled, “Lives Worth Living: Addressing the Fentanyl Crisis, Protecting Critical Lifelines, and Combatting Discrimination Against Those with Disabilities.”

 

Key Document

Opening Statement from Ranking Member Pallone as prepared for delivery

Opening Statement from Subcommittee Ranking Member Eshoo as prepared for delivery

 

Livestream

 

Legislation

H.R. 467, the Halt All Lethal Trafficking (HALT) of Fentanyl Act  

H.R. 498, the 9-8-8 Lifeline Cybersecurity Responsibility Act

H.R. 501, the Block, Report, And Suspend Suspicious Shipments Act

H.R. 485, the Protecting Health Care for All Patients Act of 2023

 

Witnesses

Panel I:

Kemp Chester
Senior Advisor, International Relations and Supply Reduction
Office of National Drug Control Policy (ONDCP)

Testimony

 

Dr. Neerja Gandotra
Chief Medical Officer
Substance Abuse and Mental Health Services Administration (SAMHSA)

Testimony

 

Jon DeLena
Associate Administrator, Business Operations 
Drug Enforcement Administration (DEA)

Testimony

 

Panel II:

Kandi Pickard
President and CEO
National Down Syndrome Society (NDSS)

Testimony

 

Frederick Isasi, J.D. MPH
Executive Director
Families USA

Testimony

 

Molly Cain
Parent Advocate

Testimony

 

Dr. Stephen Loyd
Chief Medical Officer
Cedar Recovery

Testimony

 

Dr. Timothy Westlake
Emergency Medicine Physician

Testimony

 

Issues:Health